Regencell Bioscience's Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy TrialBusiness Wire • 09/12/22
Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment PeriodBusiness Wire • 05/18/22
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEOBusiness Wire • 05/16/22
Regencell Describes Their Traditional Chinese Medicine ("TCM") Treatments and Recent Efficacy Trial Results in New Video Interview on SNN NetworkAccesswire • 03/01/22
Regencell Bioscience's COVID-19 Candidate Shows Encouraging Action On Mild To Moderate SymptomsBenzinga • 02/17/22
Regencell Bioscience's Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy TrialBusiness Wire • 02/17/22
Regencell Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of DirectorsBusiness Wire • 12/13/21
Regencell Bioscience Holdings Limited Announces Over $1 Million Ordinary Share Purchase by CEOBusiness Wire • 11/22/21
Regencell Bioscience Holdings Limited Included in the MSCI World Micro Cap IndexBusiness Wire • 11/22/21
Regencell Bioscience Stock Jumps On Formation Of COVID-19 Treatment Focused Joint VentureBenzinga • 09/02/21
Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID TreatmentBusiness Wire • 09/02/21
Regencell Bioscience Holdings Limited Announces Partial Exercise of Underwriter's Over-Allotment OptionBusiness Wire • 08/20/21
Regencell Bioscience Holdings Limited Announces Closing of Initial Public OfferingBusiness Wire • 07/20/21
Regencell Bioscience Holdings Limited Announces Pricing of Approximately $21.9 Million Initial Public OfferingBusiness Wire • 07/15/21